Astrazeneca Stock News

AstraZeneca's (AZN) stock has risen 26.9% in the past year compared with an increase of 22.3% for the industry.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne Anaptys Bio, Inc. (NASDAQ: ANAB) said the Ph

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne Anaptys Bio, Inc. (NASDAQ: ANAB ) said the Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. The study will be discontinued. "Although the results of this ACORN trial are disappointing, I would like to thank all of the patients, investigators, staff and our employees involved in conducting this trial," said Hamza Suria , AnaptysBio''s CEO. "We look forward to further advancement of imsidolimab for the treatment of GPP and hidradenitis suppurativa. AnaptysBio continues to utilize its strong cash position in a capital-efficient manner to advance three wholly-owned clinical-stage programs with $90 to $100 million anticipated net cash burn in 2022." The stock was declining 10.48% to $25.46 in premarket trading. Biogen, Eisai Amend Economic Agreement Related To Aduhelm Biogen, Inc. (NASDAQ: BIIB ) and Eisai Co.

Merck & Co. Inc. MRK, +0.27% said Tuesday that it will stop a clinical trial evaluating Keytruda with AstraZeneca's AZN, +0.15% AZN, -0.76% Lynparza in advanced prostate cancer patients because the co

Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.

FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

NEW YORK , March 14, 2022 /PRNewswire/ -- Polaris Market Research recently published a research report on "Sleeping Aids Market Share, Size, Trends, Industry Analysis Report, By Product (Mattresses & Pillows, Sleep Laboratories, Medications, Sleep Apnea Devices); By Sleep Disorders; By Region; Segment Forecast, 2022 - 2030" in its research database. According to research report published by Polaris Market Research, the global Sleeping Aids Market size expected to reach to USD 118.31 Billion by 2030 from USD 64.08 Billion in 2021, at a compound annual growth rate (CAGR) of 7.1% during forecast period 2022 to 2030. Report Overview: Sleeping aids products are used in the form of medicines and medical devices to ensure proper monitoring, diagnosis, and treatment for sleep disturbances and disorders. Symptoms of sleep disorders include excessive daytime sleepiness, irregular breathing, or increased movement during sleep. Sleep disorders causes problems with the quality, timing, and amount of sleep, which result in irregular breathing and abnormal sleeping behaviors.

The FDA has declined to approve AstraZeneca Plc''s (NASDAQ: AZN ) asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and stuffiness. The FDA has issued a complete response letter following AstraZeneca''s application to extend the use of Fasenra … Full story available on Benzinga.com

NEW YORK , March 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AZN, BUD, MRNA, LMT, and WFC. … Full story available on Benzinga.com

FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

The FDA has approved AstraZeneca Plc''s (NASDAQ: AZN ) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK ) to treat patients with early-stage breast cancer with certain mutations. The agency approved Lynparza (olaparib) for patients with a form of genetically mutated high-risk early-stage breast cancer called BRCA-mutated HER2-negative, who have already been treated with chemotherapy either before or after surgery. The approval was based on results from … Full story available on Benzinga.com

The U.S. Food and Drug Administration rejected to approve the expanded use of AstraZeneca''s (AZN) asthma therapy Fasenra to treat patients with inadequately controlled…

Astrazeneca PLC found using ticker (AZN) have now 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 70 and 59.5 calculating the average target price we see 66.98. Given that the stocks previous close was at 60.9 this now indicates there is a potential upside of 10.0%. The day 50 moving average is 58.73 and the 200 moving average now moves to 58.51. The market cap for the company is $188,315m. Find out more information at: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets=AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $207,116m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

AstraZeneca Plc said on Monday the U.S. Food and Drug Administration (FDA) rejected its asthma medicine, Fasenra, for treatment of chronic rhinosinusitis with nasal polyps, a condition where benign growths can cause pain and stuffiness. The London-listed drugmaker said the FDA had issued a complete response letter following its application to extend use of the […]